Retrophin secures European orphan drug designation for RE-024 to treat pantothenate kinase-associated neurodegeneration
"Receiving orphan drug status in the EU is another encouraging step in the development of RE-024 for the treatment of PKAN," said Alvin Shih, M.D., executive vice president
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.